| Bioactivity | Revexepride is a highly selective 5-HT4 receptor agonist, and a potential inducer of CYP3A4 enzyme, used for the treatment of gastroesophageal reflux disease. | ||||||||||||
| Invitro | The human CYP isoenzymes are involved in the metabolism of revexepride, which is mainly metabolized in vitro in humans by CYP3A4 (99.9%) with a minor contribution of CYP2D6 (0.1%). Revexepride exhibits direct inhibition of human CYP3A4 in vitro with IC50 values of 16-49 μM[1]. | ||||||||||||
| Name | Revexepride | ||||||||||||
| CAS | 219984-49-3 | ||||||||||||
| Formula | C21H32ClN3O4 | ||||||||||||
| Molar Mass | 425.95 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. David Pierce, et al. A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults. Drug Des Devel Ther. 2015; 9: 1257-1268. |
Revexepride
CAS: 219984-49-3 F: C21H32ClN3O4 W: 425.95
Revexepride is a highly selective 5-HT4 receptor agonist, and a potential inducer of CYP3A4 enzyme, used for the treatme
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.